Rockwell Medical, Inc.

    Jurisdiction
    United States
    LEI
    529900Y6YUB5X93MMD77
    ISIN
    US7743743004 (RMTI)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. Read full profile

    Fundamentals

    Net revenue
    €75.03M
    Gross margin
    17.5%
    EBIT
    -€1.10M
    EBIT margin
    -1.5%
    Net income
    -€1.79M
    Net margin
    -2.4%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 453K $511.89K +11K Buy

    Earnings Calls

    Latest earnings call: May 14, 2024 (Q1 2024)

    Add to watchlist

    Notifications